Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration.
The dopamine (DA) and DOPAC levels were measured in cerebrospinal fluid (CSF) using a radioenzymatic method. The influence of a specific monoamine oxidase B inhibitor (deprenyl) on changes in DA and DOPAC levels was studied in untreated patients or after L-dopa administration. A single dose of deprenyl alone did not change the CSF DA and DOPAC levels, a three days' treatment, however, decreased both the DOPAC and DA concentrations. The acute administration of L-dopa caused an increase in CSF DA and DOPAC levels. The changes were smaller following repeated treatment. Deprenyl diminished the increase in DOPAC level after repeated L-dopa administration.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000134:cerebrospinal fluid*; D000328:Adult; D001545:Benserazide / Q000494:pharmacology; D004298:Dopamine / Q000134:cerebrospinal fluid*; D006801:Humans; D007980:Levodopa / Q000494:pharmacology*; D008995:Monoamine Oxidase / Q000097:blood; D010627:Phenethylamines / Q000494:pharmacology*; D010648:Phenylacetates / Q000134:cerebrospinal fluid*; D012642:Selegiline / Q000494:pharmacology*
D010627:Phenethylamines; D010648:Phenylacetates; D015102:3,4-Dihydroxyphenylacetic Acid; D012642:Selegiline; D007980:Levodopa; D001545:Benserazide; D008995:Monoamine Oxidase; D004298:Dopamine